RxDoctor Payments Data

Kendall Douglass, MD

Cardiovascular Disease · Mobile, ALNPI 1316334634

Payments from drug & device makers

$1,848in general payments, 2019–2025

Across 65 payments — averaging $28.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$493
  • AstraZeneca$290
  • E.r. Squibb & Sons, L.L.C.$165
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$160
  • Heartflow, Inc.$94
  • Pfizer$87
  • plus $558 from 12 others

What the payments were for

  • Food & beverage$1,53983%
  • Education$30917%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,848 in reported general payments places this provider in the 35th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$667,345
Medicare patients
1,704
Services billed
30,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban636$700,137
EntrestoSacubitril/Valsartan301$356,626
FarxigaDapagliflozin Propanediol228$228,931
Repatha SureclickEvolocumab163$149,333
XareltoRivaroxaban73$112,590
JardianceEmpagliflozin101$92,967
MultaqDronedarone Hcl36$39,056
Atorvastatin Calcium833$11,491
Rosuvastatin Calcium534$8,543
Ranolazine ErRanolazine81$8,207
Metoprolol Succinate633$8,206
Nitroglycerin282$6,978
Dabigatran EtexilateDabigatran Etexilate Mesylate21$6,325
Losartan Potassium378$4,060
ClopidogrelClopidogrel Bisulfate280$3,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$87$700,137636 claims
NovartisEntresto$86$356,626301 claims
AstraZenecaFarxiga$290$228,931228 claims
Johnson & JohnsonXarelto$26$112,59073 claims
Boehringer IngelheimJardiance$67$92,967101 claims
Sanofi-aventis U.S. LLCMultaq$36$39,05636 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →